271 related articles for article (PubMed ID: 36926178)
1. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
Kong W; Yang X; Shu Y; Li S; Song B; Yang K
Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant
Simon MS; Sfeir MM; Calfee DP; Satlin MJ
Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31548187
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China.
Shi X; Fu J; Li X; Lv Q; Wan X; Xu Q
J Infect Public Health; 2023 Mar; 16(3):361-367. PubMed ID: 36689854
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
Kongnakorn T; Wagenlehner F; Falcone M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Int J Antimicrob Agents; 2019 Nov; 54(5):633-641. PubMed ID: 31202921
[TBL] [Abstract][Full Text] [Related]
7. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for
De Benedetto I; Shbaklo N; Vicentini C; Zotti CM; De Rosa FG; Corcione S
Microorganisms; 2023 Apr; 11(5):. PubMed ID: 37317076
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
Tichy E; Torres A; Bassetti M; Kongnakorn T; Di Virgilio R; Irani P; Charbonneau C
Clin Ther; 2020 May; 42(5):802-817. PubMed ID: 32349879
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae.
Pérez-Nadales E; Fernández-Ruiz M; Natera AM; Gutiérrez-Gutiérrez B; Mularoni A; Russelli G; Pierrotti LC; Pinheiro Freire M; Falcone M; Tiseo G; Tumbarello M; Raffaelli F; Abdala E; Bodro M; Gervasi E; Fariñas MC; Seminari EM; Castón JJ; Marín-Sanz JA; Gálvez-Soto V; Rana MM; Loeches B; Martín-Dávila P; Pascual Á; Rodríguez-Baño J; Aguado JM; Martínez-Martínez L; Torre-Cisneros J;
Am J Transplant; 2023 Jul; 23(7):1022-1034. PubMed ID: 37028515
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T; Tsergouli K; Lowrie K
Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant
Ahmed F; Abraham B; Kamal Saeed N; Mohamed Naser H; Sridharan K
Crit Care Res Pract; 2024; 2024():3427972. PubMed ID: 38868174
[TBL] [Abstract][Full Text] [Related]
16. Carbapenem-resistant Klebsiella pneumoniae Osteoarthritis in Two Preterm Infants Treated With Ceftazidime-avibactam.
Pu W; Fan L; Zhang Y; You D; Li M; Ma L
Pediatr Infect Dis J; 2023 Dec; 42(12):1124-1127. PubMed ID: 37725810
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection.
Xiao S; Fu Q; Miao Y; Zhao M; Lu S; Xu J; Zhao W
Front Microbiol; 2023; 14():1198926. PubMed ID: 37664109
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients.
Shi Y; Hu J; Liu P; Wang T; Wang H; Liu Y; Cao Q; Zuo X
Infect Dis Ther; 2021 Dec; 10(4):2721-2734. PubMed ID: 34652713
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
Gu J; Xu J; Zuo TT; Chen YB
J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
